M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout Pharmaceutical TechnologyJ J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class.OncologyRead full story pharminent July 31, 2026 (Last updated: August 3, 2026) Pharmaceutical Technology J J strikes its deal with Sail as the in vivo CAR-T space becomes increasingly crowded, with several big pharma players betting on the class. Oncology Read full story Post navigation Previous: Amgen’s Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and StrokesNext: Outlook Therapeutics Secures FDA Approval for LYTENAVA Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
